Blood treatment equipment

Abstract

The utility model belongs to the field of medical instruments, and particularly relates to blood treatment equipment. The blood treatment equipment comprises a blood treatment pond which is a sealed container and is provided with at least one first opening for plasma to enter and at least one second opening for blood to enter and exit; the plasma generator is used for generating plasma, and an outlet of the plasma generator is communicated with the blood treatment pond through the first opening; and the blood passage is communicated with the blood treatment tank through the second opening. According to the equipment disclosed by the invention, the plasma can be used for treating the blood, so that the oxidation resistance of the blood can be improved, and an equipment foundation is provided for the plasma to become a new health-care and treatment means.

Description

Technical Field

[0001] The present disclosure belongs to the field of medical devices, and specifically relates to a blood processing device. Background Art

[0002] By processing blood, it can play a comprehensive conditioning role on pathogens, microorganisms, senescent cells, and malignant tumors in the body, and can also regulate the sub-health state of the human body, prevent atherosclerosis, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, endocrine diseases, allergies, immune diseases and chronic diseases. Currently, it is widely used in internal medicine, surgery, gynecology, tumors, immunity and pain medicine, and has achieved good results.

[0003] The current devices for improving the antioxidant properties of blood mainly involve "Oxygen Autohemotherapy", which extracts blood into a special antioxidant blood bag, injects a certain concentration and amount of medical ozone (O3), shakes it evenly, and then returns it to the body to enhance the antioxidant capacity of the blood. However, ozone blood purification requires the use of high concentrations of ozone. If used improperly or the treatment time is too long, it may cause oxygen poisoning, manifested as symptoms such as headache, dizziness, nausea, and vomiting.

[0004] Atmospheric pressure plasma jet is a typical atmospheric pressure non-equilibrium plasma, which often uses rare gases (such as He, Ar, etc.) as working gases. Due to its unique discharge structure, the plasma jet, under the combined action of airflow and electric field, makes the gas breakdown at a lower voltage, and makes the plasma generated in the downstream open area outside the electrode, overcoming the limitations of traditional plasma in application due to the discharge gap and vacuum environment. Plasma jet has the advantages of high electron temperature (0.1 ~ 1eV), low gas temperature (300 ~ 350K), high active particle content, good controllability, etc., and has broad application prospects in pollution control, disinfection and sterilization, plant breeding and clinical medicine.

[0005] After Laroussi M confirmed the sterilization effect of plasma in 1996, the biological and medical applications of plasma have received widespread attention. As an interdisciplinary subject combining physics, biology and medicine, plasma biomedicine has shown great development potential and application prospects. - OH - 、NO - and N 3-The plasma is widely used in sterilization, skin disease treatment, tumor treatment, oral medicine and wound healing by using the oxidative / nitrogenic stress effect produced by plasma, and many clinical experiments have been carried out on this basis. It is worth noting that the role of ROS and RNS in the body is bidirectional. They are not only important apoptosis inducing factors, but more importantly, when they are at physiological concentrations, they also play the role of signal factors and participate in many pathological and physiological processes of the body, such as cell differentiation, proliferation, body defense and aging. Therefore, by controlling the plasma parameters and treatment conditions, when the active particles produced by it are at physiological concentrations, the plasma has a positive effect on cell proliferation, differentiation and damage protection.

[0006] However, there is currently no research on the use of plasma to enhance the antioxidant properties of blood. Utility Model Content

[0007] The research team of this disclosure has been committed to studying the physiological functions of appropriate amounts of plasma and its application in disease models. In the early stage, it was the first in the world to discover and confirm the neuroprotective function of plasma and its therapeutic effect in ischemic brain injury (Chen Y, Yang B, Liu Y, et al. Application of an atmospheric pressure plasma jet in a rat model of ischaemic stroke: Design, optimisation, and characteristics [J]. High Voltage, 2023, 8 (2): 315-325.).

[0008] The present disclosure unexpectedly discovered that plasma treatment can increase the anti-oxidation capacity of blood. Based on this discovery, the present disclosure provides a blood treatment device and method.

[0009] Specifically, the present disclosure first provides a blood treatment device, which includes:

[0010] A blood treatment pool, the blood treatment pool is a sealed container, and is provided with at least one first opening for plasma to enter, and at least one second opening for blood to enter and exit;

[0011] a plasma generator, the plasma generator being used to generate plasma, wherein an outlet of the plasma generator is connected to the blood treatment pool through the first opening; and

[0012] A blood passage is connected to the blood processing pool through the second opening.

[0013] Furthermore, the present disclosure also provides a blood treatment method, which includes: using the aforementioned blood treatment equipment, inputting blood into a blood treatment pool through the blood pathway, using the plasma generated by the plasma generator to treat the blood, and then outputting the treated blood through the blood pathway.

[0014] The device disclosed in the present invention can realize the plasma treatment of blood, which is beneficial to improve the anti-oxidation capacity of blood and provides a device foundation for plasma to become a new health care and treatment method. Compared with the traditional method, the treatment method of the device disclosed in the present invention is more direct, simple, more accurate, reduces many unnecessary side effects, and is safer. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the specific embodiments of the present disclosure or the technical solutions in the prior art, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0016] Figure 1 This is a schematic diagram of the blood processing equipment in Example 1 of the present disclosure.

[0017] Figure 2 This is a schematic diagram of the blood processing equipment in Example 2 of the present disclosure.

[0018] Figures 1-2 In the figure, the numerical labels refer to the following: 1. blood treatment pool; 11. first opening; 12. second opening; 13. third opening; 2. plasma generator; 3. blood passage; 31. blood collection passage; 32. blood transfusion passage; 33. liquid storage structure.

[0019] Figure 3 Schematic diagram of the serum treatment method in the disclosed experimental example.

[0020] Figure 4 It is the proteomic sequencing result in the test example disclosed in the present invention; wherein, A is the cluster analysis result; and B is the volcano map of differential proteins.

[0021] Figure 5 It is the quantified GPX1 protein expression result in the test example disclosed in the present invention; wherein, A is the quantified GPX1 expression level; and B is the targeted proteomics mass spectrometry detection result.

[0022] Figure 6These are the results of the change of antioxidant capacity with plasma treatment time in the test example disclosed in the present invention; wherein, A is the change of the total amount of glutathione in serum with plasma treatment time; and B is the change of the NO content in serum with plasma treatment time.

[0023] Figure 7 This is the result of the change of Gpx activity value in the experimental example disclosed in the present invention with plasma treatment. DETAILED DESCRIPTION

[0024] The specific embodiments of the present disclosure are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present disclosure, and are not used to limit the present disclosure. Those skilled in the art may make various modifications and changes to the present disclosure without departing from the scope or spirit of the present disclosure. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0025] Unless otherwise indicated, the meaning of all terms (including technical and scientific terms) used to disclose the present disclosure is the same as that commonly understood by those of ordinary skill in the art to which the present disclosure belongs. By way of further guidance, the following definitions are used to better understand the teachings of the present disclosure. The terms used herein in the specification of the present disclosure are only for the purpose of describing specific embodiments and are not intended to limit the present disclosure.

[0026] Explanation of terms

[0027] The terms "and / or", "or / and", and "and / or" used in the present disclosure have a selection range that includes any one of two or more related listed items, and also includes any and all combinations of related listed items, wherein the any and all combinations include any combination of two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in the present application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0028] As used in this disclosure, the terms "comprising," "including," and "including" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements, or method steps.

[0029]

[0013] Numerical ranges recited in this disclosure as endpoints include all numbers and fractions subsumed within that range, as well as the recited endpoints.

[0030] The present disclosure relates to concentration values, and the meaning includes fluctuations within a certain range. For example, fluctuations can be allowed within a corresponding precision range. For example, 2%, a fluctuation within the range of ±0.1% can be allowed. For values ​​that are large or do not require too fine control, the meaning is also allowed to include greater fluctuations. For example, 100mM, fluctuations within the range of ±1%, ±2%, ±5%, etc. can be allowed. Involving molecular weight, the meaning is allowed to include fluctuations of ±10%.

[0031] In the present disclosure, descriptions such as "plurality" and "multiple" refer to quantities greater than or equal to 2 unless otherwise specified.

[0032] In the present disclosure, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0033] In the present disclosure, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of the present disclosure.

[0034] In the present disclosure, "optionally", "optional", "optionally", "optionally", "optional", "optional", "optional" means optional, that is, it means to be selected from any of the two parallel schemes of "yes" or "no". If multiple "optional" or "optional" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" or "optional" is independent.

[0035] In this disclosure, the term "plasma" refers to the fourth state of matter consisting of free electrons and positive ions. In plasma, electrons are separated from the nuclei of atoms, forming free electrons with negative charges, while ions with positively charged nuclei also exist. This highly ionized state makes plasma exhibit many special properties, such as conductivity, luminescence, response to electromagnetic fields, etc. The active particles (such as O2 - OH - 、NO - and N 3- The interaction of components such as charged particles with processed materials such as gases, liquids and tissues can form relatively stable reactive oxygen species (ROS) and reactive nitrogen species (RNS).

[0036] In the present disclosure, the term "atmospheric pressure low temperature plasma" is a non-thermal plasma, which is usually generated by discharge at normal temperature and atmospheric pressure. The atmospheric pressure low temperature plasma may also be referred to as atmospheric pressure plasma, low temperature plasma, atmospheric pressure cold plasma, atmospheric pressure non-equilibrium plasma, atmospheric pressure low temperature non-equilibrium plasma, etc. When the above-mentioned similar names appear, they are substantially equivalent to the atmospheric pressure low temperature plasma mentioned in the present disclosure.

[0037] In the present disclosure, the term "atmospheric pressure plasma jet (APPJ)" refers to a technology that generates and uses plasma under atmospheric pressure conditions. This technology, through its unique electrode structure, causes the gas (such as helium, argon and / or air) to break down at a relatively low voltage under the combined action of airflow and electric field, and causes plasma to be generated in the downstream open area outside the electrode. As an example, the electrode structure is a needle-ring dielectric barrier discharge (DBD) structure, in which a tungsten needle is used as a high-voltage electrode connected to a sinusoidal high-voltage AC power supply, and an aluminum ring (about 3 mm wide) surrounds a quartz tube and serves as a ground electrode. In some specific embodiments, the electrode structure can also be a corona discharge structure.

[0038] In the present disclosure, the terms "air flow control" and "flow control" include control over the opening and closing of a channel and control over the flow of a medium in a channel.

[0039] Blood processing equipment

[0040] The present disclosure first provides a blood treatment device, which includes:

[0041] A blood treatment pool, the blood treatment pool is a sealed container, and is provided with at least one first opening for plasma to enter, and at least one second opening for blood to enter and exit;

[0042] a plasma generator, the plasma generator being used to generate plasma, wherein an outlet of the plasma generator is connected to the blood treatment pool through the first opening; and

[0043] A blood passage is connected to the blood processing pool through the second opening.

[0044] In a specific embodiment, the first opening and the second opening can each independently be one or more (eg, 2, 3, 4, etc.).

[0045] In some embodiments, the plasma generator is used to generate atmospheric pressure low-temperature plasma.

[0046] In some embodiments, the plasma generator is used to generate a plasma jet (APPJ) by discharging helium, argon and / or air at atmospheric pressure.

[0047] In combination with the aforementioned functional limitations and common knowledge in the art, those skilled in the art can determine the specific structure of the plasma generator mentioned in the present disclosure during specific implementation.

[0048] In some embodiments, a temperature sensor and / or an ozone concentration sensor is provided in the plasma generator or on the connecting passage between the outlet of the plasma generator and the first opening; a power control element and / or a first airflow control element are provided on the plasma generator, wherein the power control element is used to control the power switch and / or power parameters of the plasma generator; and the first airflow control element is used to control the gas flow rate of the air inlet passage. By providing a temperature sensor and / or an ozone concentration sensor, the temperature and ozone concentration of the plasma can be monitored accordingly, which is more conducive to controlling the treatment effect of the plasma on the blood.

[0049] In some embodiments, a gas filtering and sterilizing element is provided on the gas inlet passage of the plasma generator, which can further avoid contamination of the blood.

[0050] In some embodiments, a time control element is provided on the plasma generator, and the time control element is used to control the time when the plasma generator generates plasma.

[0051] In some embodiments, a pressure sensor is provided in the blood treatment pool, at least one third opening for exhaust gas is provided on the blood treatment pool, and a second airflow control element is provided at the third opening to control the gas flow rate of the third opening. In this way, the exhaust gas generated by the reaction of plasma and blood can be discharged in time, avoiding the negative impact of high pressure or exhaust gas on blood treatment.

[0052] In some specific embodiments, an exhaust gas recovery structure is connected to the third opening.

[0053] In some specific embodiments, a check valve and / or a gas filtering and sterilizing element is provided at the third opening or on the connecting passage between the third opening and the waste gas recovery structure.

[0054] In some embodiments, a liquid level sensor is provided in the blood processing pool, and a flow control element is provided on the second opening or the blood passage, and the flow control element is used to control the flow of blood.

[0055] In some embodiments, at least one liquid storage structure is provided on the blood passage, so as to avoid the influence of the blood processing flow on the blood collection or transfusion speed.

[0056] In some specific embodiments, flow control elements may be provided on the blood passages on both sides of the liquid storage structure to control the blood processing speed and the blood collection and transfusion speed respectively.

[0057] In some embodiments, a constant temperature heating element and / or a liquid oscillating element is provided inside the blood treatment tank and / or the liquid storage structure.

[0058] In some embodiments, the blood passage includes a blood collection passage and a blood transfusion passage, and the blood collection passage and the blood transfusion passage are respectively connected to the blood processing pool through different second openings.

[0059] In some embodiments, a detachable blood collection element and a blood transfusion element are provided at the free end of the blood passage.

[0060] In some embodiments, a detachable blood collection element is disposed at the free end of the blood collection passage, and a detachable blood transfusion element is disposed at the free end of the blood transfusion passage.

[0061] In some embodiments, an anticoagulant adding element is provided on the blood passage (preferably a blood sampling passage), and the anticoagulant adding element is used to add anticoagulant into the blood passage.

[0062] In some embodiments, blood sampling and blood transfusion are achieved through a blood pathway. In this case, the blood pathway needs to be used for blood sampling and blood transfusion in sequence. In some embodiments, the blood pathway includes a blood sampling pathway and a blood transfusion pathway. In this case, the blood sampling and blood transfusion processes can be performed simultaneously.

[0063] In some specific embodiments, the blood collection element and / or the blood transfusion element are used to connect to a blood bag; in some specific embodiments, the blood collection element and / or the blood transfusion element are used to connect to a body blood vessel (usually a venous vessel). Based on the above settings, the blood processing device of the present disclosure can be used for exogenous blood processing, and can also be used for autologous blood processing.

[0064] In some embodiments, the blood processing device is further provided with a central controller and / or at least one alarm;

[0065] The central controller and / or the alarm is communicatively connected to at least one selected from a temperature sensor, an ozone concentration sensor, a liquid level sensor, and a pressure sensor;

[0066] The central controller is communicatively connected to at least one selected from the power control element, the first airflow control element, the time control element, the second airflow control element, and the flow control element.

[0067] In some specific embodiments, the blood treatment device is provided with at least one alarm, and the alarm is communicatively connected to at least one selected from a temperature sensor, an ozone concentration sensor, a liquid level sensor, and a pressure sensor, so that an alarm for abnormal situations can also be realized.

[0068] In some specific embodiments, the blood treatment device is provided with a central controller, and the central controller is connected to at least one selected from a temperature sensor, an ozone concentration sensor, a liquid level sensor, and a pressure sensor; the central controller is connected to at least one selected from the power control element, the first airflow control element, the time control element, the second airflow control element, and the flow control element. In this way, although there is no alarm information, the occurrence of abnormal situations can still be avoided through the participation and regulation of the central controller.

[0069] In some specific embodiments, the blood treatment device is provided with a central controller and at least one alarm; the central controller and the alarm are connected to at least one selected from a temperature sensor, an ozone concentration sensor, a liquid level sensor, and a pressure sensor; the central controller is connected to at least one selected from the power control element, the first airflow control element, the time control element, the second airflow control element, and the flow control element. In this way, not only can an alarm be realized for abnormal situations, but also the occurrence of abnormal situations can be avoided in time through the participation and regulation of the central controller.

[0070] The components of the control elements themselves referred to in this disclosure are well known in the art.

[0071] In some specific embodiments, the power control element includes: a switching device for controlling the on and off state of the circuit, such as an electromagnetic relay, a circuit breaker, etc.; a regulator for adjusting the voltage, current, frequency and / or power in the circuit, such as a potentiometer, a voltage regulator, etc.; and optionally, a protection device for protecting the circuit and equipment from problems such as overload and short circuit, such as a fuse, an overload protector, etc.

[0072] In some specific embodiments, the first airflow control element (or the second airflow control element) includes: an airflow regulating valve for regulating the flow rate or pressure of the gas, usually controlled manually or automatically; and optionally, a pressure gauge for measuring the pressure of the gas.

[0073] In some specific embodiments, the time control element includes: a timer, a device for setting and controlling specific time intervals, which can be mechanical, electronic or computer-controlled; and optionally, a clock, which is used to display the current time and can be integrated with other control systems to achieve time synchronization and coordination.

[0074] In some specific embodiments, the flow control element includes: a flow regulating valve, which is used to adjust the flow rate of the fluid to meet specific process requirements; a flow sensor, which is used to measure the flow rate of the fluid, can monitor the fluid flow in real time and feed back to the control system; a flow meter, which is used to measure the flow rate of the fluid and display the results, and is usually used in conjunction with the flow regulating valve to achieve precise control and regulation of the flow rate.

[0075] The control elements mentioned in the present disclosure can be controlled manually or by a central controller independently.

[0076] In some embodiments, the blood treatment device further comprises a display screen for displaying information such as the status, parameters, and operation interface of the blood treatment device. In some embodiments, the user can control and operate the device through the display screen by means of a touch screen or buttons, such as adjusting parameters, starting and stopping the device, etc.

[0077] In some specific embodiments, the blood processing device further comprises elements related to cleaning, disinfection and / or sterilization, so as to perform necessary cleaning, disinfection and / or sterilization during replacement of the processing object.

[0078] In some specific embodiments, the blood processing device also includes elements related to CRRT (continuous renal replacement therapy) to further expand the application field.

[0079] Those skilled in the art can combine the above-mentioned solutions with common sense to obtain other implementations of the blood treatment device.

[0080] Blood processing methods

[0081] The present disclosure also provides a blood treatment method, which includes: using the blood treatment device described in any of the aforementioned schemes, inputting blood into a blood treatment pool through the blood pathway, using the plasma generated by the plasma generator to treat the blood, and then outputting the treated blood through the blood pathway.

[0082] In some embodiments, the blood processing method comprises:

[0083] Acquiring detection information of the temperature sensor and / or the ozone concentration sensor;

[0084] Determine whether the detection information exceeds a threshold range; preferably, the upper limit of the temperature threshold is 40°C, more preferably the upper limit of the temperature threshold is 37°C, and the lower limit of the temperature threshold is 25°C; the upper limit of the ozone concentration threshold is 0.02ppm;

[0085] When the detection information exceeds a threshold range, at least one of the following operations is performed: i) an alarm instruction is sent to the alarm; ii) a control instruction is sent to a power control element and / or a first airflow control element on the plasma generator to adjust the temperature and / or ozone concentration of the plasma to within a threshold range.

[0086] In some embodiments, the blood processing method comprises:

[0087] Acquiring detection information of the pressure sensor;

[0088] Determining whether the detection information exceeds a threshold range;

[0089] When the detection information exceeds a threshold range, at least one of the following operations is performed: i) sending an alarm instruction to the alarm; ii) sending a control instruction to the second airflow control element to reduce the pressure of the blood treatment pool to within a threshold range.

[0090] In some embodiments, the blood processing method comprises:

[0091] Acquiring detection information of the liquid level sensor;

[0092] Determining whether the detection information exceeds a threshold range;

[0093] When the detection information meets the threshold range requirement, at least one of the following operations is performed: i) sending a control instruction to the flow control element to stop the blood from entering and exiting the blood control pool; ii) sending a control instruction to the power control element and / or the first airflow control element on the plasma generator to process the blood using the plasma generated by the plasma generator;

[0094] When the detection information exceeds a threshold range, at least one of the following operations is performed: i) sending an alarm instruction to the alarm; ii) sending a control instruction to the flow control element to control the liquid level of the blood treatment pool within the threshold range.

[0095] In some embodiments, the blood processing method comprises:

[0096] Acquiring preset configuration information for the plasma generator to generate plasma and time information of the time control element; the preset configuration information includes preset time requirements and preset control instructions;

[0097] Determining whether the time information meets the preset time requirement;

[0098] When the time information meets the preset time requirement, at least one of the following operations is performed: i) sending a preset control instruction to the power control element and / or the first airflow control element on the plasma generator to control the power switch and / or power parameters of the plasma generator; ii) sending a preset control instruction to the flow control element to control the flow of blood in and out of the blood control pool.

[0099] The steps mentioned in the above scheme are relatively independent in realizing the functions, so in some embodiments, those skilled in the art can combine them as needed to obtain more embodiments of the blood treatment method.

[0100] Example

[0101] The embodiments of the present disclosure will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present disclosure and are not intended to limit the scope of the present disclosure. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance given in the present disclosure, and can also be based on the experimental manuals or conventional conditions in the art, and can also be based on other experimental methods known in the art, or according to the conditions recommended by the manufacturer.

[0102] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0103] Example 1

[0104] This embodiment provides a blood treatment device (such as Figure 1 As shown), it includes a blood treatment pool 1, a plasma generator 2, a blood passage 3 and four alarms.

[0105] The blood treatment pool 1 is a sealed container, and is provided with a first opening 11 for plasma entry, a second opening 12 for blood entry and exit, and a third opening 13 for exhaust gas discharge. A constant temperature heating element and a liquid oscillating element are provided inside the blood treatment pool 1.

[0106] The plasma generator 2 is used to generate a plasma jet (APPJ) by discharging helium gas through a needle ring dielectric barrier discharge (DBD) structure under atmospheric pressure, and the outlet of the plasma generator 2 is connected to the blood treatment pool 1 through the first opening 11. A temperature sensor and an ozone concentration sensor are provided on the connection channel between the outlet of the plasma generator 2 and the first opening 11; an electric control element, a first airflow control element and a time control element are provided on the plasma generator 2, wherein the electric control element is used to control the electric switch and electric parameters of the plasma generator 2, the first airflow control element is used to control the gas flow rate of the air inlet channel, and the time control element is used to control the time when the plasma generator 2 generates plasma. A gas filtering and sterilizing element is provided on the air inlet channel of the plasma generator 2.

[0107] The blood passage 3 is connected to the blood treatment pool 1 through the second opening 12. A liquid level sensor is provided in the blood treatment pool 1, and a flow control element is provided on the blood passage 3, and the flow control element is used to control the flow of blood. A liquid storage structure 33 is provided on the blood passage 3, and a constant temperature heating element and a liquid oscillation element are provided inside the liquid storage structure 33. An anticoagulant adding element is provided on the blood passage 3, and the anticoagulant adding element is used to add anticoagulant to the blood passage 3. A detachable blood collection element and a blood transfusion element are provided at the free end of the blood passage 3.

[0108] The third opening 13 is connected to an exhaust gas recovery structure, and a check valve and a gas filtering and sterilizing element are provided on the connection channel between the third opening 13 and the exhaust gas recovery structure.

[0109] The alarm is respectively connected to the temperature sensor, the ozone concentration sensor, the liquid level sensor and the pressure sensor for communication.

[0110] This embodiment further provides a blood treatment method, which includes:

[0111] Using the above blood treatment equipment, the power control element and the first airflow control element on the plasma generator 2 are turned on, and when the parameters of the plasma generated by the plasma generator 2 are stable, the blood is input into the blood treatment pool 1 through the blood passage 3, and after the blood is treated with the plasma generated by the plasma generator 2, the treated blood is output through the blood passage 3. The blood collection and blood transfusion process is realized through a blood passage 3, and blood collection and blood transfusion need to be performed respectively.

[0112] At the same time, the conditions of each alarm are monitored manually. When the alarm connected to the temperature sensor (the upper limit of the temperature threshold is set to 37°C and the lower limit of the temperature threshold is set to 25°C) or the ozone concentration sensor (the upper limit of the ozone concentration threshold is set to 0.02ppm) sounds an alarm, the temperature or ozone concentration of the plasma is adjusted to within the threshold range through the power control element and the first airflow control element. When the alarm connected to the pressure sensor sounds an alarm, the pressure of the blood treatment pool 1 is reduced to within the threshold range through the second airflow control element. When the alarm connected to the liquid level sensor sounds an alarm, the liquid level of the blood treatment pool 1 is controlled within the threshold range through the flow control element.

[0113] Example 2

[0114] This embodiment provides a blood treatment device (such as Figure 2 As shown), it includes a blood treatment pool 1, a plasma generator 2, a blood passage 3, a central controller and four alarms.

[0115] The blood treatment pool 1 is a sealed container, and is provided with a first opening 11 for plasma entry, two second openings 12 for blood entry and exit, and a third opening 13 for exhaust gas discharge. A constant temperature heating element and a liquid oscillating element are provided inside the blood treatment pool 1.

[0116] The plasma generator 2 is used to generate a plasma jet (APPJ) by discharging helium gas through a needle ring dielectric barrier discharge (DBD) structure under atmospheric pressure, and the outlet of the plasma generator 2 is connected to the blood treatment pool 1 through the first opening 11. A temperature sensor and an ozone concentration sensor are provided on the connection channel between the outlet of the plasma generator 2 and the first opening 11; an electric control element, a first airflow control element and a time control element are provided on the plasma generator 2, wherein the electric control element is used to control the electric switch and electric parameters of the plasma generator 2, the first airflow control element is used to control the gas flow rate of the air inlet channel, and the time control element is used to control the time when the plasma generator 2 generates plasma. A gas filtering and sterilizing element is provided on the air inlet channel of the plasma generator 2.

[0117] The blood passage 3 includes a blood collection passage 31 and a blood transfusion passage 32, and the blood collection passage 31 and the blood transfusion passage 32 are connected to the blood treatment pool 1 through different second openings 12, respectively. A liquid level sensor is provided in the blood treatment pool 1, and a flow control element is provided on the blood passage 3, and the flow control element is used to control the flow of blood. A liquid storage structure 33 is provided on the blood collection passage 31 and the blood transfusion passage 32, respectively, and a constant temperature heating element and a liquid oscillation element are provided inside the liquid storage structure 33. An anticoagulant adding element is provided on the blood collection passage 31, and the anticoagulant adding element is used to add anticoagulant to the blood passage 3. A detachable blood collection element is provided at the free end of the blood collection passage 31, and a detachable blood transfusion element is provided at the free end of the blood transfusion passage 32.

[0118] The third opening 13 is connected to an exhaust gas recovery structure, and a check valve and a gas filtering and sterilizing element are provided on the connection channel between the third opening 13 and the exhaust gas recovery structure.

[0119] The alarm is respectively connected to the temperature sensor, the ozone concentration sensor, the liquid level sensor and the pressure sensor for communication.

[0120] The central controller is connected to the alarm and is connected to the temperature sensor, the ozone concentration sensor, the liquid level sensor, the pressure sensor, the power control element, the first airflow control element, the time control element, the second airflow control element, and the flow control element respectively;

[0121] This embodiment further provides a blood treatment method, which includes:

[0122] Using the above blood treatment equipment, the power control element and the first airflow control element on the plasma generator 2 are turned on, and when the parameters of the plasma generated by the plasma generator 2 are stable, the blood is input into the blood treatment pool 1 through the blood passage 3, and after the blood is treated with the plasma generated by the plasma generator 2, the treated blood is output through the blood passage 3. The blood collection and blood transfusion processes can be carried out simultaneously.

[0123] At the same time, the blood treatment equipment is centrally managed and controlled by the central controller, and the central controller can perform the following steps 1) to 4):

[0124] 1) Acquire detection information of the temperature sensor and the ozone concentration sensor; determine whether the detection information exceeds a threshold range; set the upper limit of the temperature threshold to 37°C and the lower limit of the temperature threshold to 25°C; the upper limit of the ozone concentration threshold is 0.02ppm; when the detection information exceeds the threshold range, perform the following operations: i) send an alarm instruction to the alarm; ii) send a control instruction to the power control element on the plasma generator 2 to adjust the temperature and ozone concentration of the plasma to within the threshold range.

[0125] 2) Acquire detection information of the pressure sensor; determine whether the detection information exceeds a threshold range; when the detection information exceeds the threshold range, perform the following operations: i) send an alarm instruction to the alarm; ii) send a control instruction to the second airflow control element to reduce the pressure of the blood treatment pool 1 to within the threshold range.

[0126] 3) Obtaining the detection information of the liquid level sensor; determining whether the detection information exceeds a threshold range; when the detection information meets the threshold range requirement, performing at least one of the following operations: i) sending a control instruction to a flow control element to stop the blood from entering and exiting the blood control pool; ii) sending a control instruction to a power control element and a first airflow control element on the plasma generator 2 to process the blood using the plasma generated by the plasma generator 2; when the detection information exceeds the threshold range, performing the following operations: i) sending an alarm instruction to the alarm; ii) sending a control instruction to the flow control element to control the liquid level of the blood treatment pool 1 within the threshold range.

[0127] 4) obtaining preset configuration information of the plasma generator 2 for generating plasma and time information of the time control element; the preset configuration information includes preset time requirements and preset control instructions; judging whether the time information meets the preset time requirements; when the time information meets the preset time requirements, performing at least one of the following operations: i) sending preset control instructions to the power control element and the first airflow control element on the plasma generator 2 to control the power switch and power parameters of the plasma generator 2; ii) sending preset control instructions to the flow control element to control the flow of blood in and out of the blood control pool.

[0128] Test example

[0129] This test example provides test data on the effect of plasma on blood treatment. The production of plasma can be used as an implementation of the method for using the plasma generator defined above, but not as a limitation on the scope of protection of the present disclosure.

[0130] 1. Experimental materials:

[0131] 1. Production of plasma (APPJ): The atmospheric pressure plasma jet (APPJ) is generated by a needle-ring dielectric barrier discharge (DBD) structure. In this setup, a tungsten needle is used as a high-voltage electrode connected to a sinusoidal high-voltage AC power supply, while a 3 mm wide aluminum ring surrounds the quartz tube and serves as a ground electrode. For more details on the plasma source, see Chen Y, Yang B, Liu Y, et al. Application of an atmospheric pressure plasma jet in arat model of ischaemic stroke: Design, optimisation, and characteristics [J]. High Voltage, 2023, 8 (2): 315-325. The experimental discharge conditions are: the driving voltage is fixed at 5.6 kV (Vs = 5.6 kV), the gas flow rate is fixed at 1400 sccm (Q = 1400 sccm), and the driving frequency is fixed at 5 kHz (f = 5 kHz). A digital oscilloscope (DPO4104B; Tektronix) and a high-voltage probe (P6015A; Tektronix) were used; a Tektronix probe (TPP1000; Tektronix) was used to calculate the discharge current, taking into account the displacement current. Helium was used as the working gas, and its flow rate was controlled by a mass flow controller (MFC, SevenStarCS200). A fiber optic spectrometer (AvaSpec-ULS3648) was used to monitor the emission spectrum of APPJ.

[0132] 2. Animals: Specific pathogen-free (SPF) male adult Sprague-Dawley rats (weight 250-300 g, n = 6). All rats were housed in a controlled environment with 3 animals per cage; 12-h light / dark cycle; temperature, 22 ± 2°C; humidity, 50% to 60%, with adequate food and water.

[0133] 2. Experimental methods:

[0134] 1. After anesthetizing 3 rats, blood was collected from the abdominal aorta. After collecting blood, place the blood collection tube on ice and let it stand for 30 minutes. After the blood in the tube coagulates, centrifuge it at 1000g for 10 minutes, and the supernatant is the serum. The serum of the same rat was divided into EP tubes according to the treatment group and control group numbers, with a capacity of 200 microliters per tube, and protease inhibitors were quickly added to ensure that the protein was not decomposed. Among them, the treatment group numbers are: T1, T2, T3, T4, T5, and the control group number is: C. Each group was set up with 3 replicates according to the different sources of rats, and the results were taken as the average of the 3 replicates.

[0135] 2. Use a plasma device to treat the serum in the EP tubes numbered T1, T2, T3, T4, and T1. Figure 3 As shown, the height at which the jet just touches the serum level is appropriate, and treatment is performed according to the set time gradient of 15S, 30S, 60S, 120S, and 240S, respectively. The control group C is not subjected to plasma treatment (0S).

[0136] 3. Proteomic sequencing was performed on the serum collected from the control group C (0S) and the treatment group T4 (120S) in order to test the therapeutic effect through changes in the proteome.

[0137] 4. In order to verify the antioxidant capacity in the blood, the test kits (GSH and GSSG test kits, NO test kits) of Biyuntian Company were selected to test the changes in active particles in the blood of the control group C and the treatment group T1-T5 with the change of plasma treatment time to determine the effect of plasma treatment on the antioxidant capacity of the blood. Among them, the GSH and GSSG test kits are used to detect the total amount of glutathione in the serum to detect the antioxidant capacity, and the NO test kit is used to detect the value of nitric oxide in the serum to determine whether the active nitrogen oxide components change with plasma treatment. At the same time, the Gpx activity value in the control group C and the treatment group T4 (120S) was tested by the test kit to determine the effect of plasma treatment on the catalytic activity of Gpx in the blood.

[0138] 5. Statistical analysis was performed using R statistical software (4.0.5) (https: / / www.r-project.org / ). Data are presented as mean ± standard error (SEM). For normally distributed and non-normally distributed data, unpaired Student's t test and nonparametric Mann-Whitney U test were used to determine differences, respectively. A probability value of P < 0.05 was considered statistically significant.

[0139] 3. Experimental Data

[0140] 1. According to the proteomics sequencing report, GPX1, an antioxidant factor that was significantly upregulated, was screened out. Figure 4-5 shown.

[0141] in Figure 4 A in the figure is cluster analysis, which screens out differentially expressed genes. The red part is significantly upregulated, and the blue part is significantly downregulated. It can be seen intuitively that GPX1 shows an upregulated trend. Figure 2 B in the figure is a differential protein volcano map, red represents significant upregulation, and blue represents significant downregulation. It can be seen that GPX1 is in the red upregulated part.

[0142] Figure 5A in the figure is the quantified GPX1 expression level. It can be seen that the GPX1 protein level in the treated group (T is the average of six repeated groups) after plasma treatment is significantly increased compared with the untreated group (C is the average of six repeated groups). Figure 5 B in the figure is the result of targeted proteomics mass spectrometry detection. PRM targeted proteomics is a mass spectrometry technology designed to quantitatively measure the presence and abundance of specific proteins in complex samples. It combines the high sensitivity and high selectivity of mass spectrometry technology to provide accurate and reproducible quantitative results. Figure 5 The value given by the original peptide in A is more accurate. Figure 5 From B, we can see that the total amount of GPX1 has increased significantly.

[0143] According to the literature, GPX1 has a strong antioxidant effect (PMID: 36937839). The protein encoded by this gene belongs to the glutathione peroxidase family, whose members catalyze the reduction of organic hydrogen peroxide and hydrogen peroxide (H2O2) through glutathione, thereby protecting cells from oxidative damage (see: Yuan Lin. Study on eukaryotic expression and antioxidant effect of GPx1 [D]. Jilin University, 2019.). At the same time, glutathione peroxidase can reduce tissue damage caused by inflammatory response. It can remove excess oxidative substances, inhibit the release of inflammatory cytokines, reduce the degree of inflammatory effects, and resist cell apoptosis (PMID: 16132718). It can also prevent lipid peroxidation, maintain the integrity and stability of cell membranes, and prevent lipid peroxidation damage to cell membranes (PMID: 21636625).

[0144] 2. The test results of the kit showed that the total amount of glutathione in serum increased with the increase of plasma treatment time ( Figure 6 A in the figure, the content of active nitrogen oxide components also increases with the increase of plasma treatment time ( Figure 6 B). The activity value of Gpx (glutathione peroxidase) at 120s was significantly higher than that of untreated ( Figure 7 ). It can be seen that plasma treatment can increase the antioxidant capacity of blood.

[0145] The above-mentioned embodiments only express several implementation methods of the present disclosure, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present disclosure, and these all belong to the protection scope of the present disclosure.

Claims

1. A blood treatment device, characterized in that: It includes: A blood treatment pool, the blood treatment pool is a sealed container, and is provided with at least one first opening for plasma to enter, and at least one second opening for blood to enter and exit; A plasma generator, the plasma generator is used to generate plasma, and an outlet of the plasma generator is connected to the blood treatment pool through the first opening; and A blood passage is connected to the blood processing pool through the second opening.

2. The blood treatment device according to claim 1, characterized in that: The plasma generator is used to generate atmospheric pressure low-temperature plasma.

3. The blood treatment device according to claim 1, characterized in that: The plasma generator is used for generating a plasma jet by discharging helium, argon and / or air under atmospheric pressure.

4. The blood treatment device according to claim 1, characterized in that: A temperature sensor and / or an ozone concentration sensor is provided in the plasma generator or on a connecting passage between the outlet of the plasma generator and the first opening; The plasma generator is provided with a power control element and / or a first airflow control element, wherein the power control element is used to control the power switch and / or power parameters of the plasma generator; and the first airflow control element is used to control the gas flow of the air inlet channel.

5. The blood treatment device according to claim 1, characterized in that: A gas filtering and sterilizing element is arranged on the air inlet passage of the plasma generator.

6. The blood treatment device according to claim 1, characterized in that: A time control element is provided on the plasma generator, and the time control element is used to control the time when the plasma generator generates plasma.

7. The blood treatment device according to claim 1, characterized in that: A pressure sensor is provided in the blood treatment pool, at least one third opening for exhaust gas discharge is provided on the blood treatment pool, and a second airflow control element is provided at the third opening for controlling the gas flow of the third opening.

8. The blood treatment device according to claim 1, characterized in that: A liquid level sensor is provided in the blood treatment pool, and a flow control element is provided on the second opening or the blood passage, and the flow control element is used to control the flow of blood.

9. The blood treatment device according to claim 1, characterized in that: At least one liquid storage structure is arranged on the blood passage.

10. The blood treatment device according to claim 9, characterized in that A constant temperature heating element and / or a liquid oscillating element is arranged inside the blood treatment pool and / or the liquid storage structure.

11. The blood treatment device according to claim 1, characterized in that: The blood passage comprises a blood collection passage and a blood transfusion passage, and the blood collection passage and the blood transfusion passage are respectively connected to the blood processing pool through different second openings.

12. The blood treatment device according to claim 11, characterized in that A detachable blood sampling element and a blood transfusion element are arranged at the free end of the blood passage.

13. The blood treatment device according to claim 11, characterized in that An anticoagulant adding element is provided on the blood passage, and the anticoagulant adding element is used to add anticoagulant into the blood passage.

14. The blood treatment apparatus according to claim 4, 6, 7 or 8, characterized in that The blood processing device is also provided with a central controller and / or at least one alarm; The central controller and / or the alarm is communicatively connected to at least one selected from a temperature sensor, an ozone concentration sensor, a liquid level sensor, and a pressure sensor; The central controller is communicatively connected to at least one selected from the group consisting of a power control element, a first airflow control element, a time control element, a second airflow control element, and a flow control element.

Images